Superstring Capital Management’s Cogent Biosciences COGT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$13.3M Buy
343,284
+118,126
+52% +$4.13M 8.39% 1
2026
Q1
$8.67M Sell
225,158
-141,080
-39% -$5.21M 6.19% 3
2025
Q4
$13M Buy
366,238
+4,830
+1% +$136K 6.96% 4
2025
Q3
$5.19M Sell
361,408
-601,543
-62% -$7.13M 5.11% 7
2025
Q2
$6.91M Buy
962,951
+188,230
+24% +$1.04M 8.19% 1
2025
Q1
$4.64M Sell
774,721
-136,144
-15% -$1.07M 5.52% 7
2024
Q4
$7.1M Buy
+910,865
New +$9.08M 6.15% 6

Other funds holding COGT

Superstring Capital Management's COGT Position: Q2 2026 in Review

Superstring Capital Management increased its Cogent Biosciences (COGT) stake by 52% in Q2 2026, buying an estimated $4.13M and bringing the position to 343,284 shares worth $13.3M. The position accounts for 8.39% of the portfolio, ranked #1.

Superstring Capital Management first reported a position in COGT in Q4 2024 and has held it in 7 quarters since. 322 funds tracked by Wall St. Rank hold COGT as of Q2 2026.

  • Superstring Capital Management held 343,284 shares of Cogent Biosciences worth $13.3M as of Q2 2026.
  • Superstring Capital Management bought 118,126 Cogent Biosciences shares in Q2 2026, an estimated $4.13M.
  • Cogent Biosciences made up 8.39% of Superstring Capital Management's portfolio in Q2 2026, its #1 holding.
  • Superstring Capital Management first reported a position in Cogent Biosciences in Q4 2024 and has held it in 7 quarters since.
  • 322 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2026.

Based on Superstring Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.